Tyme Technologies (NASDAQ: TYME)
Some price data may be temporarily unavailable.
Tyme Technologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tyme Technologies Company Info
TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.
News & Analysis
Why Tyme Technologies Stock Is Taking Off Today
The company closed a $100 million public stock offering.
Why Tyme Stock Got Demolished Today
The clinical-stage biotech provides investors with a quarterly update.
Why Tyme Technologies Stock Is Crushing It Today
The U.S. Patent and Trademark Office is on Tyme's side.
Here's Why Tyme Technologies Fell 35% on Friday
The devil is in the clinical-trial details.
Why Tyme Technologies Is Skyrocketing
Shares rose sharply after management released upbeat clinical data and scheduled a conference call.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.